PDMR shareholdings

Diaceutics PLC
04 May 2023
 

4 May 2023

 

Diaceutics PLC

("Diaceutics" or "the Company")

 

PDMR shareholdings

 

Diaceutics PLC, (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, has been informed that Jordan Clark, Chief Commercial Officer, a Person Discharging Managerial Responsibilities ('PDMR'), has on 28 April 2023 sold 3,000 Ordinary Shares in the Company each, at a price of 102 pence per Ordinary Share.

 

 

Enquiries:

 

Diaceutics PLC  


Peter Keeling, Chief Executive Officer

Nick Roberts, Chief Financial Officer 

Via Alma PR 





Stifel Nicolaus Europe Limited (Nomad & Broker)

Tel: +44 (0)20 7710 7600

Ben Maddison


Nick Harland


Nick Adams






Alma PR

Tel: +44(0)20 3405 0205

Caroline Forde

diaceutics@almapr.co.uk

Kieran Breheny


Matthew Young

Kinvara Verdon


 

 

About Diaceutics

 

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.

 

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.

 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Jordan Clark

2

Reason for notification


a.

Position/Status

Chief Commercial Officer

b.

Initial notification/

Amendment

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

Diaceutics PLC

b.

LEI

213800VEWQBB39ZB8J81

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of £ 0.002 each

 

ISIN:   GB00BJQTGV64

b.

Nature of the transaction

Sale of Ordinary Shares

c.

Price(s) and volume(s)







Price(s)

Volume(s)


102 pence

3,000



d.

Date of the transaction

28 April 2023

e.

Place of the transaction

AIM Market of the London Stock Exchange

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 

Companies

Diaceutics (DXRX)
UK 100

Latest directors dealings